Literature DB >> 32007519

Surgical and endoscopic management options for patients with GERD based on proton pump inhibitor symptom response: recommendations from an expert U.S. panel.

Andrew J Gawron1, Reginald Bell2, Barham K Abu Dayyeh3, F P Buckley4, Kenneth Chang5, Christy M Dunst6, Steven A Edmundowicz7, Blair Jobe8, John C Lipham9, Dan Lister10, Marcia Irene Canto11, Michael S Smith12, Anthony A Starpoli13, George Triadafilopoulos14, Thomas J Watson15, Erik Wilson16, John E Pandolfino17, Alexander Kaizer7, Zoe Van De Voorde7, Rena Yadlapati18.   

Abstract

BACKGROUND AND AIMS: The objective of this study was to examine expert opinion and agreement on the treatment of distinct GERD profiles from surgical and therapeutic endoscopy perspectives.
METHODS: We used the RAND/University of California, Los Angeles Appropriateness Method over 6 months (July 2018 to January 2019) to assess the appropriateness of antireflux interventions among foregut surgeons and therapeutic gastroenterologists. Patients with primary atypical or extraesophageal symptoms were not considered. Patient scenarios were grouped according to their symptom response to proton pump inhibitor (PPI) therapy. The primary outcome was appropriateness of an intervention.
RESULTS: Antireflux surgery with laparoscopic fundoplication (LF) and magnetic sphincter augmentation (MSA) were ranked as appropriate for all complete and partial PPI responder scenarios. Transoral incisionless fundoplication was ranked as appropriate in complete and partial PPI responders without a hiatal hernia. Radiofrequency energy was not ranked as appropriate for complete or partial responders. There was lack of agreement between surgery and interventional gastroenterology groups on the appropriateness of LF and MSA for PPI nonresponders. Rankings for PPI nonresponders were similar when results from impedance-pH testing on PPI therapy were available, except that LF and MSA were not ranked as appropriate for PPI nonresponders if the impedance-pH study was negative.
CONCLUSIONS: This work highlights areas of agreement for invasive therapeutic approaches for GERD and provides impetus for further interdisciplinary collaboration and trials to compare and generate novel and effective treatment approaches and care pathways, including the role of impedance-pH testing in PPI nonresponders.
Copyright © 2020 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32007519      PMCID: PMC7321870          DOI: 10.1016/j.gie.2020.01.037

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  14 in total

Review 1.  Epidemiology of gastroesophageal reflux disease.

Authors:  Joel H Rubenstein; Joan W Chen
Journal:  Gastroenterol Clin North Am       Date:  2013-12-27       Impact factor: 3.806

2.  Management options for patients with GERD and persistent symptoms on proton pump inhibitors: recommendations from an expert panel.

Authors:  Rena Yadlapati; Michael F Vaezi; Marcelo F Vela; Stuart J Spechler; Nicholas J Shaheen; Joel Richter; Brian E Lacy; David Katzka; Philip O Katz; Peter J Kahrilas; Prakash C Gyawali; Lauren Gerson; Ronnie Fass; Donald O Castell; Jenna Craft; Luke Hillman; John E Pandolfino
Journal:  Am J Gastroenterol       Date:  2018-04-24       Impact factor: 10.864

3.  The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus.

Authors:  Nimish Vakil; Sander V van Zanten; Peter Kahrilas; John Dent; Roger Jones
Journal:  Am J Gastroenterol       Date:  2006-08       Impact factor: 10.864

4.  The burden of gastrointestinal and liver diseases, 2006.

Authors:  Nicholas J Shaheen; Richard A Hansen; Douglas R Morgan; Lisa M Gangarosa; Yehuda Ringel; Michelle T Thiny; Mark W Russo; Robert S Sandler
Journal:  Am J Gastroenterol       Date:  2006-07-18       Impact factor: 10.864

5.  Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial.

Authors:  Reginald Bell; John Lipham; Brian Louie; Valerie Williams; James Luketich; Michael Hill; William Richards; Christy Dunst; Dan Lister; Lauren McDowell-Jacobs; Patrick Reardon; Karen Woods; Jon Gould; F Paul Buckley; Shanu Kothari; Leena Khaitan; C Daniel Smith; Adrian Park; Christopher Smith; Garth Jacobsen; Ghulam Abbas; Philip Katz
Journal:  Gastrointest Endosc       Date:  2018-07-18       Impact factor: 9.427

Review 6.  Effectiveness of proton pump inhibitors in nonerosive reflux disease.

Authors:  Bonnie B Dean; Anacleto D Gano; Kevin Knight; Joshua J Ofman; Ronnie Fass
Journal:  Clin Gastroenterol Hepatol       Date:  2004-08       Impact factor: 11.382

7.  Gastroesophageal Acid Reflux Control 5 Years After Antireflux Surgery, Compared With Long-term Esomeprazole Therapy.

Authors:  Jan G Hatlebakk; Frank Zerbib; Stanislas Bruley des Varannes; Stephen E Attwood; Christian Ell; Roberto Fiocca; Jean-Paul Galmiche; Stefan Eklund; Göran Långström; Tore Lind; Lars R Lundell
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-27       Impact factor: 11.382

Review 8.  Modern diagnosis of GERD: the Lyon Consensus.

Authors:  C Prakash Gyawali; Peter J Kahrilas; Edoardo Savarino; Frank Zerbib; Francois Mion; André J P M Smout; Michael Vaezi; Daniel Sifrim; Mark R Fox; Marcelo F Vela; Radu Tutuian; Jan Tack; Albert J Bredenoord; John Pandolfino; Sabine Roman
Journal:  Gut       Date:  2018-02-03       Impact factor: 23.059

Review 9.  Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group.

Authors:  S Roman; C P Gyawali; E Savarino; R Yadlapati; F Zerbib; J Wu; M Vela; R Tutuian; R Tatum; D Sifrim; J Keller; M Fox; J E Pandolfino; A J Bredenoord
Journal:  Neurogastroenterol Motil       Date:  2017-03-31       Impact factor: 3.598

10.  Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial.

Authors:  L Lundell; S Attwood; C Ell; R Fiocca; J-P Galmiche; J Hatlebakk; T Lind; O Junghard
Journal:  Gut       Date:  2008-05-09       Impact factor: 23.059

View more
  5 in total

1.  Transoral incisionless fundoplication is cost-effective for treatment of gastroesophageal reflux disease.

Authors:  Thomas R McCarty; Pichamol Jirapinyo; Lyndon P James; Sanchit Gupta; Walter W Chan; Christopher C Thompson
Journal:  Endosc Int Open       Date:  2022-07-15

2.  Beyond Proton Pump Inhibitors and Nissen Fundoplication: Minimally Invasive Alternatives for Gastroesophageal Reflux Disease.

Authors:  Reginald C W Bell
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-11

Review 3.  Antireflux mucosal intervention (ARMI) procedures for refractory gastroesophageal reflux disease: a systematic review and meta-analysis.

Authors:  Jen-Hao Yeh; Ching-Tai Lee; Min-Hung Hsu; Chi-Wen Lin; Po-Jen Hsiao; Chien-Lin Chen; Wen-Lun Wang
Journal:  Therap Adv Gastroenterol       Date:  2022-04-29       Impact factor: 4.802

4.  Ambulatory Reflux Monitoring Guides Proton Pump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: A Clinical Trial.

Authors:  Rena Yadlapati; Melina Masihi; C Prakash Gyawali; Dustin A Carlson; Peter J Kahrilas; Billy Darren Nix; Anand Jain; Joseph R Triggs; Michael F Vaezi; Leila Kia; Alexander Kaizer; John E Pandolfino
Journal:  Gastroenterology       Date:  2020-09-16       Impact factor: 22.682

Review 5.  Endoscopic anti-reflux therapy for gastroesophageal reflux disease.

Authors:  Enrique Rodríguez de Santiago; Eduardo Albéniz; Fermin Estremera-Arevalo; Carlos Teruel Sanchez-Vegazo; Vicente Lorenzo-Zúñiga
Journal:  World J Gastroenterol       Date:  2021-10-21       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.